SC 44463
Latest Information Update: 17 Jan 1997
At a glance
- Originator Pharmacia Corporation
- Class Osteoporosis therapies
- Mechanism of Action Collagenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Postmenopausal osteoporosis
Most Recent Events
- 17 Jan 1997 No-Development-Reported for Postmenopausal osteoporosis in USA (Unknown route)
- 08 Nov 1996 Preclinical development for Postmenopausal osteoporosis in USA (Unknown route)